# We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.

> **NCT06001294** · — · UNKNOWN · sponsor: **Xiangcheng Zhang** · enrollment: 70 (estimated)

## Conditions studied

- Sepsis
- Septic Shock
- Acute Kidney Injury

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06001294
- **Lead sponsor:** Xiangcheng Zhang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-03
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001294, "We Collected Blood Samples From Septic Shock Patients and Measured ELABELA, Creatinine, and NGAL Levels. Survival After 7 Days Was Recorded and Analyzed to Evaluate the Potential of Serum ELABELA as an Early Diagnostic Marker for Sepsis-associated Acute Kidney Injury.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06001294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*